Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Nanobiotix, listed on Euronext Paris and Nasdaq (NBTX), has reported its outstanding shares as of March 31, 2022, at 34,875,872. The total voting rights stood at 36,317,823 gross and 36,304,866 net. The company is pioneering physics-based therapeutic approaches, notably in oncology with its lead product, NBTXR3, which has secured market authorization in Europe for soft tissue sarcoma treatment under the brand name Hensify®.
For further details, visit www.nanobiotix.com.
- Total voting rights reported at 36,317,823 gross and 36,304,866 net.
- Lead product NBTXR3 has received market authorization in Europe for soft tissue sarcoma.
- None.
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.P
Website: www.nanobiotix.com
Date |
Number of Shares
|
Total number of voting rights |
|
Total voting rights, gross (1)
|
Total voting rights, net (2) |
||
Mars 31, 2022 |
34,875,872 |
36,317,823 |
36,304,866 |
(1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
(2) The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of
***
About
Incorporated in 2003,
For more information about
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005709/en/
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com
Nanobiotix Investor Relations
SVP, Investor Relations
+1 (609) 678-7388
investors@nanobiotix.com
Media Relations
+ 33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com
US – Porter Novelli
+1 (781) 888-5106
dan.childs@porternovelli.com
Source:
FAQ
What is the total number of shares outstanding for Nanobiotix as of March 31, 2022?
How many total voting rights does Nanobiotix hold?
What product has Nanobiotix received market authorization for?